
Opinion|Videos|February 27, 2025
PEACE-3 Study Results: Study Population & Disposition
Author(s)Abhishek Tripathi, MD
An expert discusses the design and objectives of the Phase 3 PEACE-3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).
Advertisement
Episodes in this series

Please review the design and objectives of the phase 3 PEACE 3 study of ENZA + Ra-223 for ARPI-naïve mCRPC.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































